Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin c + vinblastine
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Mitomycin C + vinblastine is a chemotherapy combination regimen used primarily in the treatment of advanced or metastatic cancers. This combination has shown activity in heavily pretreated breast cancer patients and has been studied in non-small cell lung cancer. The regimen is generally well-tolerated, though caution should be taken regarding potential side effects including leucopenia, nausea, vomiting, and paresthaesia.
- Other names
- AVM
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on mitomycin c + vinblastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin c + vinblastine.